AstraZeneca Promotes Sipavibart to Prevent COVID-19 in Immunocompromised Patients

Positive Covid-19 antibody tests in immunosuppressed patients

SUPERNOVA shows that sipavibart, AstraZeneca’s long-acting antibody, significantly reduces symptomatic disease in immunocompromised patients. The results highlight its effectiveness against different variants of the virus. + read more

Hospital Sant Pau participates in the IMMUNOcare program against Covid in immunocompromised patients.

The project, promoted by AstraZeneca, aims to improve the identification of such patients, analyze and standardize their approach, and optimize immunization consultations. + read more

IBiS reveals the effectiveness of simultaneous administration of Covid and influenza vaccines

The discovery addresses concerns about possible interactions between the vaccines, which has led to uncertainty about their effectiveness when used in combination. + read more

Carlos Navarro will head AstraZeneca’s vaccines and immunotherapy division in Spain.

With a degree in pharmacy and more than two decades of experience in the pharmaceutical industry, Navarro takes on the company’s strategic direction, which is focused on developing solutions to protect the most vulnerable patients from serious infections. + read more

Positive results from the ECHO phase III study

AstraZeneca presented results from the phase III ECHO trial showing significant improvement in PFS compared with standard chemotherapy. + read more

IMMUNOcare: optimizing care for immunocompromised patients

The initiative was launched by AstraZeneca to improve the identification of such patients, analyze and standardize their approach, and optimize immunization consultations using LEAN methodology. + read more